Clinical and Economic Value of ENTYVIO® (vedolizumab): Implications for Ulcerative Colitis and Crohn Disease Management

This clinical brief was sponsored by Takeda Pharmaceuticals U.S.A., Inc,. This information is exclusively for Payer Formulary Committees or other similar entities (groups of individuals that evaluate pharmaceuticals to determine access to, and/or cost to access, a pharmaceutical product or treatment for patients in a health care system) for making decisions regarding pricing and formulary availability only. This information is not for use by medical professionals in a medical practice setting. It is not intended for health care professionals making individual patient prescribing decisions. The information presented is specific to pricing attributes only and does not address clinical attributes of the treatments mentioned.

This clinical brief provides evidence on clinical and economic considerations for ENTYVIO® (vedolizumab; Takeda Pharmaceuticals) in ulcerative colitis and Crohn disease among patients naïve to biologics and those who previously demonstrated an inadequate response to or intolerance of immunomodulators and/or anti-TNF therapies.